

Hepatic and Intestinal First-Pass Effects

Lee MiHye, Lee DaeYoung^o, Bae SooKyung, Kim EunJung, Kim YoonGyoon, Kim Sun-Ok, Lee DongHa, Lim Hong, Yoo Sung-Eun, Lee MyungGull.

College of Pharmacy, Seoul National University

The purpose of this study was to report dose-independent pharmacokinetics of KR-31543, a new neuroprotective agent for ischemia-reperfusion damage, after intravenous and oral administration and first-pass effects after intravenous, intraportal, intragastric, and intraduodenal administration in rats. After intravenous (10, 20 and 50 mg/kg) and oral (10, 20 and 50 mg/kg) administration, the pharmacokinetic parameters of KR-31543 were dose-independent. The extent of absolute oral bioavailability (F) was 27.4% at 20 mg/kg. Considering the amount of unabsorbed KR-31543 from gastrointestinal tract at 24 h (4.11%), the low F value could be due to the hepatic, gastric, and/or intestinal first-pass effects. After intravenous administration of three doses, the total body clearances were considerably slower than the reported cardiac output in rats suggesting almost negligible first-pass effect in the heart and lung in rats. The areas under the plasma concentration-time curves from time zero to time infinity (AUCs) were not significantly different between intragastric and intraduodenal administration of KR-31543, 20 mg/kg, suggesting that gastric first-pass effect of KR-31543 was almost negligible in rats. However, the values were significantly smaller (305 and 318 $\mu\text{g} \cdot \text{mL}/\text{min}$) than that after intraportal administration (494 $\mu\text{g} \cdot \text{mL}/\text{min}$) indicating considerable intestinal first-pass effect of KR-31543 in rats, approximately 40% of the oral dose. Approximately 50% of KR-31543 absorbed into the portal vein was eliminated by the liver (hepatic first-pass effect) based on intravenous and intraportal administration (the value, 50%, was equivalent to approximately 30% of oral dose). The low F value of KR-31543 after oral administration, 20 mg/kg, to rats was mainly due to considerable intestinal (approximately 40%) and hepatic (approximately 30%) first-pass effects.

[PE2-19] [04/18/2003 (Fri) 09:30 - 12:30 / Hall P]

Drug-drug interaction with DA-125 and the other anticancer drugs

Park KyungJin^o, Yoon HeaSun, Jang JiMyun, Shim HyunJoo, Kim SoonHoe, Kim WonBae

Research Laboratories, Dong-A Pharmaceutical Co. Ltd

DA-125, a novel anthracycline analog containing fluorine with decreased cardiotoxicity and increased antitumor activity of adriamycin (ADM), developed by Research Laboratories of Dong-A Pharmaceutical. DA-125, water soluble prodrug of M1, is a β -alanine derivative of M1 (FT-ADM). DA-125 was rapidly hydrolyzed to M1, and M1 was metabolized to both M2 and M3. Both M2 and M3 were further metabolized to M4. The purpose of this study is to investigate the drug-drug interaction with DA-125 and the other anticancer drugs (prednisolone, 6-thioguanine, cytarabine, vincristine) using in vivo and in vitro assay. In vitro assay, when we used rat liver homogenate S9, the pattern of DA-125 metabolism was changed a little by prednisolone and 6-thioguanine. After oral administration of DA-125 and the other anticancer drugs to rats, we examined the changes of M1, M2, M3 and M4 plasma concentration. When DA-125 was co-administrated with prednisolone to rats, AUC of M4 was increased compared with control group. Therefore, it is considered that DA-125 has the possibility of the drug-drug interaction with prednisolone.

[PE2-20] [04/18/2003 (Fri) 09:30 - 12:30 / Hall P]

The pharmacokinetics of tramadol hydrochloride in Korean healthy volunteers